A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BioNTech SE
BioNTech SE
Evopoint Biosciences Inc.
Seagen Inc.
Theolytics Limited
Imunon
Immatics US, Inc.
Bristol-Myers Squibb
Genmab
Imunon
Beijing Biotech
Parabilis Medicines, Inc.
AstraZeneca
Eikon Therapeutics
Genmab
CanariaBio Inc.
AstraZeneca
Incyclix Bio
Compugen Ltd
858 Therapeutics, Inc.
Merck Sharp & Dohme LLC
Radiopharm Theranostics, Ltd
Blue Earth Diagnostics
Eisai Inc.
AstraZeneca
Terremoto Biosciences Inc.
GlaxoSmithKline
Taiho Oncology, Inc.
Artios Pharma Ltd
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Beijing Biotech
GI Innovation, Inc.
Filamon LTD
Ensem Therapeutics
Eisai Inc.
PMV Pharmaceuticals, Inc
AstraZeneca
NeoImmuneTech
Nanjing Leads Biolabs Co.,Ltd
Qilu Pharmaceutical Co., Ltd.
Tubulis GmbH
Eli Lilly and Company
AstraZeneca
Neonc Technologies, Inc.
Genmab
Ascendis Pharma A/S
Qurient Co., Ltd.
AstraZeneca
A2 Biotherapeutics Inc.
AstraZeneca
Antiva Biosciences